Edition:
United Kingdom

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

58.63EUR
15 Jul 2019
Change (% chg)

€-0.20 (-0.34%)
Prev Close
€58.83
Open
€58.85
Day's High
€59.49
Day's Low
€58.10
Volume
1,750,186
Avg. Vol
3,650,956
52-wk High
€97.03
52-wk Low
€52.02

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and... (more)

Overall

Beta: 1.15
Market Cap(Mil.): €54,862.03
Shares Outstanding(Mil.): 932.55
Dividend: 2.80
Yield (%): 4.76

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 54.99 29.57 33.85
EPS (TTM): 1.07 -- --
ROI: 1.19 12.85 12.53
ROE: 2.30 14.07 17.18

U.S. judge slashes Roundup jury award to $25.3 million; Bayer still plans to appeal

A federal judge on Monday slashed a damages award Bayer AG owed a California man who blamed Roundup weed killer for his cancer, to $25.27 million from $80.27 million, while rejecting the company's bid for a new trial.

15 Jul 2019

U.S. judge slashes Roundup jury award to $25.3 million; Bayer still plans to appeal

A federal judge on Monday slashed a damages award Bayer AG owed a California man who blamed Roundup weed killer for his cancer, to $25.27 million (£20.19 million) from $80.27 million, while rejecting the company's bid for a new trial.

15 Jul 2019

UPDATE 3-U.S. judge slashes Roundup jury award to $25.3 mln; Bayer still plans to appeal

July 15 A federal judge on Monday slashed a damages award Bayer AG owed a California man who blamed Roundup weed killer for his cancer, to $25.27 million from $80.27 million, while rejecting the company's bid for a new trial.

15 Jul 2019

Bayer's MRI contrast agent gets FDA approval for use in cardiac disease

Bayer AG on Monday said U.S. regulators approved its contrast agent for use in magnetic resonance imaging (MRI) to assess patients with known or suspected coronary artery disease.

15 Jul 2019

Bayer's MRI contrast agent gets FDA approval for use in cardiac disease

July 15 Bayer AG on Monday said U.S. regulators approved its contrast agent for use in magnetic resonance imaging (MRI) to assess patients with known or suspected coronary artery disease.

15 Jul 2019

Brazil cotton farmers sue Bayer over patent on GMO seed

SAO PAULO Brazilian cotton producers in the state of Mato Grosso on Thursday sued Bayer AG , seeking to cancel the chemical company's patent protection for its Bollgard II RR Flex genetically modified cotton seed, according to a statement sent to Reuters.

11 Jul 2019

UPDATE 1-Brazil cotton farmers sue Bayer over patent on GMO seed

SAO PAULO, July 11 Brazilian cotton producers in the state of Mato Grosso on Thursday sued Bayer AG, seeking to cancel the chemical company's patent protection for its Bollgard II RR Flex genetically modified cotton seed, according to a statement sent to Reuters.

11 Jul 2019

Brazil cotton farmers to challenge patent rights of Bayer GMO seed - newspaper

SAO PAULO, July 11 Brazilian cotton producers in the state of Mato Grosso plan to file a lawsuit requesting cancellation of a patent protection related to Bayer AG's Bollgard II RR Flex genetically modified cotton seed, newspaper Valor Econômico reported on Thursday.

11 Jul 2019

Elliott outspends rivals as corporate activism turns to Germany

FRANKFURT/BOSTON Elliott Management Corp has invested more than rivals in its push for corporate change so far this year and there has been an increasing focus among activist investors on German companies.

11 Jul 2019

UPDATE 1-Elliott outspends rivals as corporate activism turns to Germany

* Elsewhere in Europe, response to activism mixed (Adds Elliott quotes, background)

10 Jul 2019

Earnings vs. Estimates